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Abstract
Background: Data on the prevalence of dyslipidemia and attainment of goal/normal lipid levels in a Swedish
population are scarce. The objective of this study is to estimate the prevalence of dyslipidemia and attainment of
goal/normal lipid levels in patients treated with lipid modifying therapy (LMT).
Methods: This longitudinal retrospective observational study covers time periods before and after treatment. Data
were collected from 1994-2007 electronic patient records in public primary healthcare centers in Uppsala County,
Sweden. Patients were included if they had been treated with LMT and had at least one lipid abnormality
indicating dyslipidemia and if complete lipid profile data were available. Thresholds levels for lipids were defined as
per Swedish guidelines.
Results: Among 5,424 patients included, at baseline, the prevalence of dyslipidemia (≥1 lipid abnormality) was by
definition 100%, while this figure was 82% at follow-up. At baseline, 60% had elevated low-density lipoprotein
(LDL-C) combined with low high-density lipoprotein (HDL-C) and/or elevated triglycerides (TG s), corresponding
figure at follow-up was 36%. Low HDL-C and/or elevated TGs at follow-up remained at 69% for patients with type
2 diabetes mellitus (T2DM), 50% among patients with coronary heart disease (CHD) and 66% among patients with
10 year CHD risk >20%. Of the total sample, 40% attained goal levels of LDL-C and 18% attained goal/normal levels
on all three lipid parameters.
Conclusions: Focusing therapy on LDL-C reduction allows 40% of patients to achieve LDL-C goal and helps
reducing triglyceride levels. Almost 60% of patients experience persistent HDL-C and/or triglyceride abnormality
independently of LDL-C levels and could be candidates for additional treatments.
Background
Dyslipidemia is one of the major risk factors for cardio-
vascular disease (CVD) and coronary heart disease
(CHD) [1,2]. Of all the deaths in 2005 in Sweden, 42%
were caused by CVD[3]. The costs of CVD was esti-
mated to around 10% of total health care expenditures
in Sweden in 2006 [4].
Low-density lipoprotein cholesterol (LDL-C) is estab-
lished as a key causative factor in the progression of
CHD [5-7]. Low levels of high-density lipoprotein cho-
lesterol (HDL-C) have been shown to be predictive and
is an independent risk factor for developing CHD [8-10]
At different levels of LDL-C, there is an inverse associa-
tion between HDL-C and increased risk for CHD
[7,11-13] and CVD [14].
At present guidelines focus on LDL-C levels [15] and
statins are the gold standard for lowering LDL-C. How-
ever, type 2 diabetes mellitus (T2DM) and cardiovascu-
lar disease are associated with increased risk of
metabolic syndrome, which includes dyslipidemia, [16]
and the dyslipidemia in the metabolic syndrome is char-
acterized by hypertriglyceridemia and low levels of
HDL-C [17,18].
The aim of this study was to examine the prevalence
of dyslipidemia, mixed dyslipidemia (MD), treatment
patterns and attainment of goal/normal cholesterol
levels before and after initiation of lipid modifying ther-
apy (LMT).
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Methods
Study design and data collection
This was a longitudinal retrospective observational
study, which covers time periods before and after treat-
ment. The study consisted of a baseline period, 15
months prior to initiation of a lipid modifying therapy
(LMT) and a follow-up period (12-month following
LMT). In clinical primary health care practice in
Sweden, patients with chronic illnesses in stable state
usually only visit their GP once every 12 months. By
using a 15 months prescription free interval before
index date one could assume that the included indivi-
duals were naive users of LMT.
Data were collected retrospectively (1994-2007) from
electronic patient protocols using a search engine (The
Pygargus Customized eXtraction Program (CXP) to scan
patient protocols in 26 out of 30 public primary health-
care centers serving 77% of the total Uppsala county
population (322 043 in 2007) in the county of Uppsala,
Sweden.
Three CXP mediated extractions were performed in
order to identify patient protocols: patients with Interna-
tional Classification of Diseases (ICD) diagnostic code of
ICD-10 (-9) codes for dyslipidemia, prescription of a
LMT (Anatomic Therapeutic Chemical [ATC]-code
C10) and patients having existing laboratory results of
total cholesterol (TC), TG, LDL-C and HDL-C measure-
ment. The study was approved by the Regional Ethics
committee in Uppsala in May 2008 (2008/120).
Measures
The primary care data in which patients were identified
included records of care-giver contacts, laboratory mea-
surements, drug prescriptions, diagnoses and biometrics
(blood pressure, height and weight) carried out within
each centre. Lipid values captured were fasting or non-
fasting. LDL-C measurement was considered invalid if
the triglyceride value was >4.5 mmol/l.
Patients
Patients >35 years of age were included if their lipid
values indicated dyslipidemia and had initiated LMT
(ATC code C10.x) between May 1994 and June 2006
and had complete lipid profiles at baseline and at fol-
low-up. Treatment gaps of up to 6 weeks were allowed
during the follow-up period except for the first 6 weeks
post index date (initiation of LMT). A total of 5,424
patients met the criteria and were included in the study.
Definitions
For the analyses, normal and goal lipid levels were
defined according to Swedish guidelines: TC <4.5
mmol/l for patients at risk (< 5 mmol/l for non-high
risk patients), LDL-C <2,5 mmol/l (< 3.0 mmol/l for
non-risk patients), TG <1.7 mmol/l and HDL-C >1.0
and >1.3 mmol/l for men and women, respectively.
Mixed dyslipidemia (MD) is defined as abnormal levels
of more than one lipid fraction.
High-risk groups were defined as those with CHD,
T2DM without CHD, and those with 10-year CHD risk
>20% without CHD or T2DM. Patients with T2DM and
those with CHD were identified from the ICD diagnos-
tic codes. Patients with 10-year CHD risk >20% were
identified by calculating risk per Framingham Risk Score
(FRS) [19].
Statistical analyses
Descriptive analyses were performed to evaluate baseline
patient characteristics and the prevalence of dyslipide-
mia, MD and treatment patterns, using thresholds for
dyslipidemia defined above. These analyses were carried
out for the total study population as well as for sub-
groups. Chi-squared tests were carried out to detect sig-
nificance in differences in proportions between groups
at the level of P < 0.05 (two-tailed). Multivariate logistic
regressions were used to evaluate factors associated to
attainment of goal/normal lipid levels. The Statistical
Package for Social Sciences (SPSS) versions 16 and 18




Mean age of the study population was 69 years and 46%
were male (Table 1). About 30% were smokers, hyper-
tension was present in 88% and obesity in 40%. Of the
total study sample, about 40% were classified as high-
risk patients. No major differences between men and
women could be seen apart from 10-year CHD risk




Elevated TC as well as elevated LDL-C were observed
in over 90% and elevated TG were found in 61% and
66% of the total population and all high-risk patients
respectively (Table 2). Isolated elevated LDL-C was
less prevalent in high risk population compared to
total population, 24% compared to 31% (Figure 1 and
2). Low HDL-C and/or elevated TG were detected in
almost 70% of the total population and 76% of all
high-risk patients (Table 2). Low HDL-C, elevated TGs
as well as MD were most predominant in patients with
T2DM and in patients with 10-year risk for CHD
>20% (Table 3).
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Follow-up
At follow-up, dyslipidemia in at least one lipid fraction
was seen in 82% and 87% of the total and high-risk
populations respectively. Elevated TGs persisted in
roughly half of all patients, and low HDL-C was found
in about 30% of all patients and 38% of the high risk
patients. Low HDL-C and/or elevated TG persisted in
57% of the total population and 64% of the high-risk
patients, while elevated LDL-C combined with low
HDL-C and/or elevated TG was found in 36% of the
total population, and in 40% of the high-risk popula-
tion, respectively (Table 2). Isolated elevated LDL-C
was less prevalent in high risk population (23%) com-
pared to total population (25%) at follow-up (Figure 1
and 2).
Differences between high risk groups
At baseline, there were large differences between different
high risk groups in terms of prevalence of elevated TGs,
low HDL-C and MD while no major differences were seen
concerning elevated TC or LDL-C. The most prominent
differences were in the prevalence of dyslipidemia in the
group with T2DM compared to those with CHD. No
major differences were observed between patients with
T2DM and those with 10 year CHD risk >20% (Table 3).
At follow-up, differences in TC and LDL-C were pro-
minent in the group with 10-year CHD risk >20%,
where it persisted in about 70%. The prevalence of ele-
vated TGs, low HDL-C and combinations decreased
modestly and persisted to a greater extent in the groups
with T2DM and with 10-year CHD risk >20% (Table 3).
Table 1 Baseline characteristics, mean (SD) and percentage
Male (n = 2509) Female (n = 2915) Total (n = 5424)
Age (years) 68.1 (10.8) 70.5 (10.3) 69.4 (10.6)
Cardiovascular (CV) risk factors
Current smoker 29% 31% 30%
Hypertension > 140/90 mmHg or medication 87% 89% 88%
Hypertension medication use at baseline 60% 62% 61%
Baseline systolic blood pressure (mmHg) 147.1 (17.4) 150.6 (18.6) 148.9 (18.1)
Baseline diastolic blood pressure (mmHg) 85.1 (9.0) 83.9 (8.6) 84.4 (8.8)
TC (mmol/l) 6.6 (1.3) 7.1 (1.2) 6.9 (1.3)
LDL-C (mmol/l) 4.3 (1.2) 4.7 (1.2) 4.5 (1.2)
TG (mmol/l) 2.5 (2.0) 2.2 (1.5) 2.4 (1.8)
HDL-C (mmol/l) 1.2 (0.3) 1.5 (0.5) 1.4 (0.4)
HbA1c (%-units) 6.2 (1.4) 6.0 (1.4) 6.1 (1.4)
Type 2 diabetes mellitus 28% 22% 25%
Age at diabetes onset (years) 59.7 (10.1) 61.3 (10.1) 60.5 (10.1)
Diabetes duration (years) 8.9 (3.5) 9.5 (3.5) 9.2 (3.5)
Obesity (BMI ≥ 30) 38% 42% 40%
CHD (1) 11% 8% 10%
Diabetes without CHD (2) 25% 21% 23%
Framingham Risk Score >20% without CHD or diabetes (3) 12% 2% 7%
Any of the criteria (1) - (3) 46% 30% 38%
To convert the values for cholesterol to mg/dL, multiply by 1/0.02586. To convert the values for triglycerides to mg/dL, multiply by 1/0.01129.
TC = total cholesterol, LDL-C = low-density lipoprotein, TG = triglycerides, HDL-C = high-density lipoprotein.
Table 2 Prevalence of dyslipidemia at baseline and follow-up in total and all high risk populations
Total (n = 5424) All high risk (n = 2016)
Baseline Follow up Baseline Follow up
Elevated TC 95% 68% 93% 67%
Elevated LDL-C 93% 61% 93% 63%
Elevated TGs 61% 48% 66% 53%
Low HDL-C 35% 30% 44% 38%
Low HDL and/or elevated TGs 69% 57% 76% 64%
Elevated LDL-C and low HDL-C and/or elevated TGs 62% 36% 68% 40%
Elevated LDL-C and/or low HDL-C and/or elevated TGs 100% 82% 100% 87%
TC = total cholesterol, LDL-C = low-density lipoprotein, TG = triglycerides, HDL-C = high-density lipoprotein.
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Figure 2 Prevalence of lipid abnormalities before and after treatment with lipid modifying therapy in high-risk patients (n = 2,016).
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Attainment of goal/normal lipid levels
In the total study population TC and LDL-C goals were
attained by about 30% and 40%, respectively, and nor-
mal levels in TGs and HDL-C were attained by about
50% and 70% respectively. Only 18% of the total popula-
tion and 13% of the high-risk population attained goal/
normal levels for all three lipid parameters (Figure 1
and 2).
Multivariate regression models were run to determine
attainment of goal/normal levels in TC, LDL-C, TGs
and HDL-C. The basic model included following covari-
ates: age and gender, BMI, smoking, hypertension, base-
line lipid levels, history of diabetes, history of CHD, and
time on statin therapy. Non-significant variables in each
model were excluded in a stepwise manner, retaining
only age, gender and time on statin (even if non-signifi-
cant) in the final models.
Results (Table 4) suggested a slight, positive associa-
tion between age and attainment of goal/normal levels
in all lipid parameters. Female compared to male gender
was associated with significantly lower odds of attaining
normal levels in HDL-C (Odds Ratio [OR], 0.07; 95%
CI, 0.05-0.08).
Patients with T2DM had significantly lower odds of
attaining lipid goals/normal levels in any lipid parameter
than patients without T2DM. Patients with a history of
CHD had significantly lower odds of reaching goal/nor-
mal level in TC or LDL-C, than patients without history
of CHD.
Baseline lipid values were strongly associated with
attainment of goal/normal levels in all lipid parameters.
For each 0.1 mmol/l increase in TC or LDL-C at base-
line the odds of attaining goal levels decreased about 7%
(OR, 0.93; 95% CI, 0.92-0.93) and (OR, 0.93; 95% CI,
0.92-0.94) for TC and for LDL-C respectively. For each
0.1 mmol/l increase in TG at baseline the odds of
attaining normal levels was about 15% lower. Baseline
HDL-C values were strongly and positively associated to
attainment of normal levels as the odds increased by
more than 200% for each 0.1 mmol/l increase in base-
line value (OR, 2.15; 95% CI, 2.06-2.25).
Duration of statin therapy was associated to lower
odds of attaining goal/normal levels of TC, LDL-C and
TG. For each year on statin treatment the odds of
attaining TC or LDL-C goal were about 15% lower and
the odds of attaining normal levels of TGs was 6%
lower.
Dyslipidemia pharmacotherapy
Statin monotherapy was the dominating LMT with
small variations between different subgroups (Table 5).
Fibrates were mostly used among patients with T2DM
patients. The use of other therapies was equally limited.
Discussion
Main findings
Among Swedish patients, most of whom were treated
with statins only, prevalence of dyslipidemia decreased
significantly following treatment, from 95% to 68% in
patients with elevated TC and from 93% to 61% for
patients with elevated LDL-C. Isolated elevated LDL-C
was less prevalent in high risk population. Elevated TGs
persisted in about 50% and low HDL-C persisted in
about 30% at follow up for total sample, while MD
defined as prevalence of low HDL-C and/or elevated
TGs were prevalent in 60%.
Improvement in TGs was moderate and low HDL-C
persisted, showing only modest improvement following
therapy, and this was most notable in patients with
T2DM. Compared with nondiabetic patients, those with
diabetes in our study had a greater risk of experiencing
dyslipidemia involving TGs and HDL-C. This finding is



















BL FU BL FU BL FU BL FU BL FU BL FU
Elevated TC 95% 67% 90% 66% 93% 69% < 0.001 0.691 0.39 0.381 0.098 0.289
Elevated LDL-C 92% 60% 92% 65% 95% 72% 0.834 0.048 0.221 < 0.0001 0.208 0.032
Elevated TGs 72% 59% 49% 39% 74% 53% < 0.0001 < 0.0001 0.585 0.054 < 0.0001 < 0.0001
Low HDL-C 47% 42% 35% 27% 51% 36% < 0.0001 < 0.0001 0.223 0.043 < 0.0001 0.017
Low HDL and/or elevated TG’s 80% 69% 60% 50% 83% 66% < 0.0001 < 0.0001 0.435 0.294 < 0.0001 < 0.0001
Elevated LDL-C and low HDL-C and/or
elevated TG’s
73% 41% 53% 32% 77% 48% < 0.0001 < 0.0001 0.157 0.045 < 0.0001 < 0.0001
Elevated LDL-C and/or low HDL-C and/or
elevated TG’s
100% 88% 100% 83% 100% 90% 0.123 0.13 - 0.242 0.481 0.008
TC = total cholesterol, LDL-C = low-density lipoprotein, TG = triglycerides, HDL-C = high-density lipoprotein.
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supported by observations of increased TGs and low
HDL-C in other studies involving patients with diabetes
[20,21].
About 30% and 40% of all patients attained goals of
TC and of LDL-C respectively following treatment,
while only additional 5% and 10% patients attained
HDL-C and TG normal levels respectively following
treatment. Attaining lipid goal/normal levels was slightly
associated to age while not significantly associated to
gender except for attainment of normal levels in HDL-
C. History of CHD was associated with lower odds for
attainment of TC and LDL-C goals. Diagnosis of T2DM
was negatively associated to attainment of goal/normal
levels for any lipid parameter. Baseline lipid levels of
TC, LDL-C and TGs were strongly and negatively asso-
ciated to attainment of goal/normal levels in TC, LDL-C
and TGs, while baseline HDL-C was positively asso-
ciated to attainment of normal levels in HDL-C. Dura-
tion of statin therapy was negatively associated to
attainment of goal/normal lipid levels.
Findings compared to other studies
A large cohort study in northern Sweden [22] showed
that mean lipid levels (TC) have decreased significantly
during 1986-2004 from 6.4 to 5.8 mmol/l in men and
6.3 to 5.5 mmol/l in women in age group 25-64 years
and from 6.4 to 5.5 mmol/l in men and from 7.1 to 6.2
mmol/l in women in higher age group [3]. In this study
mean TC was higher for men (6.6 mmol/l) and women
(7.1 mmol/l), indicating a difference of about 1.0 mmol/l
compared to the findings in the above study. This could
be explained by the inclusion criteria in this study
where patients were selected if they were treated with
LMT and had indication of elevated lipid levels. In a
study using data up to 2003 on patients treated with a
LMT in the same county (Uppsala Sweden) as in this
study, mean TC was 7.47 mmol/l in the total popula-
tion, which could be compared to 6.9 mmol/l in this
study[23], indicating a decrease in TC lipid levels from
2003-2007. Another cohort study [24] in a Swedish
population showed that as from 2004 there is a ten-
dency to an increase in mean TC lipid levels among
both men and women [3]. This tendency could however
be an indication for regional differences in treatment
patterns, demography and socio economic factors. High
cholesterol concentrations are associated to low socio
economic status [25].
A study from France [26], where fibrates are more fre-
quently used found that regardless of LDL-C levels
38.7% had MD defined as elevated TGs and/or low
HDL-C, which corresponds to 57% in this study.
Fibrates have been shown effective in raising HDL-C
and lowering TGs [27] and this could explain some of
Table 4 Logistic regressions on goal/normal lipid level
attainment
Dependent variable Odds ratio 95% CI
TC Age 1.02 1.01 1.03
Gender 0.89 0.78 1.01
T2DM 0.73 0.63 0.85
CHD 0.55 0.45 0.69
TC 0.93 0.92 0.93
Time on statin 0.85 0.83 0.87
LDL-C Age 1.02 1.01 1.02
Gender 1.20 1.06 1.36
T2DM 0.65 0.56 0.75
CHD 0.42 0.34 0.53
LDL-C 0.93 0.92 0.94
Time on statin 0.86 0.84 0.88
TGs Age 1.01 1.01 1.02
Gender 1.05 0.92 1.20
T2DM 0.73 0.63 0.86
TGs 0.84 0.84 0.85
Time on statin 0.94 0.92 0.97
HDL-C Age 1.01 1.00 1.02
Gender 0.07 0.05 0.08
T2DM 0.70 0.58 0.83
HDL-C 2.15 2.06 2.25
Time on statin 1.02 0.99 1.05
TC = total cholesterol, LDL-C = low-density lipoprotein, TG = triglycerides,
HDL-C = high-density lipoprotein. The basic model included age and gender,
BMI. Smoking, hypertension, baseline lipid values, history of diabetes, history
of CHD and time on statin therapy (years). Insignificant variables were then
stepwise excluded. Age, gender and time on statin are considered important
to keep in model even if non significant in some models. Gender: Male = 1
(Female have higher odds to attaining LDL-C goals and lower odds for
attaining goals of HDL-C compared to males). Risk factors: T2DM = 1, no
T2DM = 0, Having CHD = 1, No CHD = 0 (Example: having T2DM is associated
with lower odds of attaining goal in any lipid parameter and having CHD is
associated with lower odds of attaining goals in TC and LDL-C).









10 year CHD risk
> 20% (n = 258)
Statins alone 93.6% 93.8% 92.5% 96.3% 95.0%
Fibrates alone 5.3% 5.8% 7.1% 2.9% 5.0%
Other monotherapy 0.9% 0.2% 0.2% 0.4% 0.0%
Combinations and other 0.3% 0.2% 0.2% 0.4% 0.0%
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the difference in findings. Another important difference
could be explained by baseline lipid profiles. Baseline
mean lipid values were lower (higher in HDL-C) 3.3,
1.46 and 1.59 mmol/l in LDL-C, HDL-C and TGs
respectively in the French study, which could be com-
pared to 4.5, 1.4, 2.4 mmol/l in this study. Lipid levels
at baseline were found to be strongly associated to
attainment of goal/normal lipid levels following treat-
ment. This finding is in line with another study where
high lipid levels at baseline were found to be strong pre-
dictors of failing to reach goal/normal levels in TC,
LDL-C and TGs and the inverse for the HDL-C [28].
A study on Swedish patients treated with statins found
that 70% of high-risk patients had at least one lipid
abnormality [29] compared to 82% in this study, a dif-
ference that could be due to different treatment patterns
at GP and specialist settings, since patients in that study
were recruited by specialists (40%) whereas in this study
patients were recruited in GP settings only.
In an earlier study[30], where goal attainment was
defined as having a TC below 5.0 mmol/l and LDL-C
level below 3.0 mmol/l (as recommended by the Swed-
ish Medical Products Agency at that time) 31% reached
goal levels, compared to 43% in this study, which could
indicate improved treatment of TC or LDL-C disorders
between study periods. In the earlier study the time per-
iod was 1993-2001 and in our study the period is 1994-
2007, a time period where acceptance and use of statins
was widely increased in Sweden. In 2003 the patent of
simvastatin expired and the price for the generic simvas-
tatin decreased to about 10% of the price of the patent
drug, which could partly explain some of the significant
increase in usage of statins.
A study with a similar design and method carried out
in the US and included 5,158 patients found that ther-
apy (primarily statins) reduced the proportion of
patients not at LDL-C goals from 77% to 22% and the
proportion with high TG levels from 34% to 20%. HDL
cholesterol levels were unchanged (49% and 50% were
less than normal levels before and after therapy respec-
tively) in the aggregate and in high-risk subgroups
(patients with coronary artery disease, diabetes, and 10-
year heart disease risk >20%). After therapy 29% of
high-risk patients were found having multiple lipid
abnormalities [31]. These findings are consistent to find-
ings in our study, however proportions of patients not
reaching LDL-C goal were higher in our study (93% to
61% before and after treatment). This difference could
partly be due to different thresholds for dyslipidemia
employed in the studies.
We also carried out analyses using the thresholds of
target/normal levels for LDL-C, HDL-C and TG speci-
fied as per National Cholesterol Education Program,
Adult Treatment Panel III (NCEP ATP III) guidelines,
LDL-C < 100 (2.59 mmol/l), 130 (3.37 mmol/l) or 160
mg/dL (4.14 mmol/l) (depending on risk factors), HDL-
C > 40 mg/dL (1.04 mmol/l) in men, > 50 mg/dL (1.30
mmol/l) in women and Triglycerides < 150 mg/dL (1.69
mmol/l), but not considered high until > 200 mg/dL
(2.26 mmol/l) [32,33]. The NCEP guidelines are slightly
different from the Swedish guidelines, threshold for
abnormal LDL-C is somewhat higher in the NCEP com-
pared to Swedish guidelines (2.59 mmol/l vs to 2.5
mmol/l). Using NCEP thresholds elevated LDL-C was
prevalent in less than 40% of total study population,
whilst this figure was over 50% in the high risk popula-
tion. These differences were the major differences com-
pared to the results using Swedish guidelines. Using
NCEP thresholds yields more consistent findings as
compared to the study carried out in the US and was
discussed above [31].
Treatment patterns and importance of addressing lipid
abnormalities
Statin therapy is established and accepted as primary
and secondary prevention [15] and the effect of statins
on lowering LDL-C as well as their effect on reducing
the risk of cardiovascular events has been widely docu-
mented [5,34-36]. Since in this study, treatment was pri-
marily targeted towards lowering LDL-C, isolated LDL-
C was less prevalent in high risk population. Low HDL-
C and elevated TGs are independent risk factors for
CHD [8,12,32,37] and abnormalities in these lipids were
not much improved in this study: Elevated TGs and low
HDL-C and combinations persisted to a large extent,
mostly in high-risk population despite LMT.
In the logistic regression analysis we found duration of
statin therapy to be negatively associated to attainment
of goal/normal levels. For each year increase on statin
treatment the odds of attaining LDL-C goal decreased
by about 10% (OR, 0,86; 95%CI, 0,84-0,87). This could
indicate lower efficacy with increasing time on treat-
ment, however better medication possession ratio was
found to be associated with a better goal attainment in
TC and in LDL-C [28]. Half of all patients on statin
treatment discontinue the medication by the end of the
first year [38]. Our findings might be influenced by fac-
tors related to patient compliance to treatment and dis-
continuation. Patients in this study were assumed to be
compliant to treatment, as they fulfilled the criteria of
refilling their prescriptions for at least one year, however
this might still not accurately reflect real compliance to
treatment. Another possible explanation could be related
to dosing. Almost 94% of all patients in this study were
treated with statins, of which 61% were treated with
simvastatin. The mean dose for those patients treated
with simvastatin was 16.74 mg, 43% were treated with
10 mg/day, 52% with 20 mg/day, 4.9% with 40 mg/day
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and only 0,1% were treated with 80 mg/day. This dosing
is in the lower range of what is recommended for
patients at high risk [15]. The doses of other statins
were also in the lower ranges.
Therapies that modify LDL-C, HDL and/or TG exist
but they are not widely utilized. Use of new medical
technology varies widely between countries but also
between different disease areas within a country [39].
The causes for variations in use of new drugs could be
divided into three broad groups, macro-or system level
determinants, service organization determinants and
clinical practice determinants [40]. Examples of determi-
nants could be spending on pharmaceuticals, role and
impact of health technology assessment, guidelines and
clinical culture and attitudes etc. Use of statins as well
as use of drugs in other therapy areas was low in Swe-
den when compared to other countries [39], which
could be an indicator and explanation for low uptake of
new drugs in general.
Some of the therapies that modify LDL-C, HDL and/
or TG are associated with limitations and might explain
the low utilization of these therapies. Fibric acid and
nicotinic derivatives are two classes with documented
effects on increasing HDL-C and association to reduced
CV events, but have limited documentation on CV out-
comes and are associated with high rates of adverse
events or tolerability issues [27]. The most common side
effects during fibrate therapy were skin reactions and
gastrointestinal symptoms, while flushing was the most
common issue during therapy on Niacin [27] and could
be major reason behind the limited use of these treat-
ment options.
Limitations and strengths
Total patients that met all predefined inclusion and
exclusion criteria and were included in the analysis were
5424, about 58% of total study population (n = 5424/
9384). The inclusion criteria of complete lipid profiles
caused an exclusion of about 21% (n = 1933/9384),
which may result in selection bias, since patients with
high CVD risk should have better documentation and a
greater probability of selection in the cohort and this
could be a limitation of generalizability. The problem of
missing complete lipid profiles was reported by other
researchers and the analytical solution used in this study
was adapted from their prior work [28]. In short, they
compared baseline lipid values for those patients with
complete lipid profiles compared to the included
patients. If baseline lipid profiles were similar they con-
cluded that those patients with complete profiles were
representative for the entire cohort. Using the same
methodology in this study no major differences in base-
line lipid values were found between excluded and
included cases. Nonetheless, one should use caution
when extrapolating these data to the general population
of patients using LMT.
Another limitation is that our analyses were on
patients who got their LMT prescription refilled for at
least one year and had complete lipid profiles, which
might thus represent a best-case scenario of goal/normal
lipid level attainment. Another possible limitation is that
it was not possible to differentiate between fasting and
non-fasting TG measurements in this study. To address
this issue LDL-C measurements were considered invalid
if the triglyceride values were >4.5 mmol/L. Furthermore
both fasting as well as non-fasting TG act as strong pre-
dictors of cardiovascular events [41].
We calculated 10-year CHD risk >20% using FRS,
since this predicts fatal and non fatal CHD events, while
the European risk classifying system, SCORE[42], only
predicts fatal events. The FRS system is widely used and
validated [19]. However, for certain populations the FRS
has been shown to overestimate risk [43-45]. In this
study only 258 of all patients (not included in patients
with T2DM or CHD) in total sample were found to be
at 10-year CHD risk >20%.
The major strength of this study is that patients were
identified from real clinical practice, which provides
insight on prevalence, treatment patterns and goal
attainment in patients with dyslipidema in Sweden and
could be of use for decision making within the health
care system. For instance, all lipid modifying agents on
the Swedish market were reviewed in 2009 by the Swed-
ish decision making body on reimbursement of pharma-
ceuticals (The Dental and Pharmaceutical Benefits
Agency, TLV). The outcomes of the review acknowl-
edged the need for drugs other than statins that could
be useful for patients as add on to a statin therapy
where statin monotherapy is not sufficient or when sta-
tins are not tolerated [46], which is an important stand
point within health policy and may help reducing the
burden of CVD.
Complete lipid profiles provide possibilities to assess
different types of disorders and can be used to identify
patients where additional treatment is needed to target
specific dyslipidemia profiles. Our findings indicate this
need in particular for patients with T2DM. In the “The
Action to Control Cardiovascular Risk in Diabetes”
(ACCORD) study however, combination treatment of
simvastatin and fenofibrate in patients with T2DM was
not found to reduce the rate of fatal cardiovascular
events, nonfatal myocardial infarction, or nonfatal
stroke, as compared with simvastatin alone [47]. How-
ever, the patients in the ACCORD study were at very
high risk for CVD, therefore findings can not be gener-
alized to all patients with T2DM. Furthermore there are
strong evidence for low HDL-C as well as elevated TGs
[8,12,32,37] besides elevated TC and LDL-C as risk
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factors for CVD and patients at risk should be consid-
ered for treatments in addition to statins that target
multiple lipid disorders.
Conclusions
Focusing dyslipidemia therapy on LDL-C reduction
allows 40% of all patients to successfully achieve LDL-C
goal and also helps reduce triglyceride levels, whereas
HDL-C and/or triglyceride abnormalities mainly persist.
Despite treatment with statins high-risk patients are still
at substantial risk of CVD events. Low HDL-C is a
known risk factor for CHD but appears to be largely
ignored despite existence of agents that raise HDL-C.
About 60% of all patients starting statin therapy could
be considered for addition of treatments that target
multiple lipid disorders. This option is most urgent for
patients with type 2 diabetes mellitus.
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